Kathleen O'Neill

Ms. Kathleen O'Neill

University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
LCLyndsey S. Crump
Lyndsey S. Crump
JFJessica L. Floyd
Jessica L. Floyd
LKLi-Wei Kuo
Li-Wei Kuo
MPMiriam D. Post
Miriam D. Post
MBMike Bickerdike
Mike Bickerdike
BBBenjamin Bitler
Benjamin Bitler
High-grade serous carcinoma (HGSC) of the fallopian tube, ovary, and peritoneum is the most common type of ovarian cancer and is predicted to be immunogenic because the presence of tumor-infiltrating lymphocytes conveys a better prognosis. However, the efficacy of immunotherapies has been limited because of the immune-suppressed tumor microenvironment (TME). Tumor metabolism and immune-suppressive metabolites directly affect immune cell function through the depletion of nutrients and activation of immune-suppressive transcriptional programs. Tryptophan (TRP) catabolism is a contributor to HGSC disease progression. Two structurally distinct rate-limiting TRP catabolizing enzymes, indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2), evolved separately to catabolize TRP. IDO1/TDO2 are aberrantly expressed in carcinomas and metabolize TRP into the immune-suppressive metabolite kynurenine (KYN), which can engage the aryl hydrocarbon receptor to drive immunosuppressive transcriptional programs. To date, IDO inhibitors tested in clinical trials have had limited efficacy, but those inhibitors did not target TDO2, and we find that HGSC cell lines and clinical outcomes are more dependent on TDO2 than IDO1. To identify inflammatory HGSC cancers with poor prognosis, we stratified patient ascites samples by IL6 status, which correlates with poor prognosis. Metabolomics revealed that IL6-high patient samples had enriched KYN. TDO2 knockdown significantly inhibited HGSC growth and TRP catabolism. The orally available dual IDO1/TDO2 inhibitor, AT-0174, significantly inhibited tumor progression, reduced tumor-associated macrophages, and reduced expression of immune-suppressive proteins on immune and tumor cells. These studies demonstrate the importance of TDO2 and the therapeutic potential of AT-0174 to overcome an immune-suppressed TME. Significance: Developing strategies to improve response to chemotherapy is essential to extending disease-free intervals for patients with HGSC of the fallopian tube, ovary, and peritoneum. In this article, we demonstrate that targeting TRP catabolism, particularly with dual inhibition of TDO2 and IDO1, attenuates the immune-suppressive microenvironment and, when combined with chemotherapy, extends survival compared with chemotherapy alone.

21 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
KOKathleen O'Neill
Kathleen O'Neill
LKLi-Wei Kuo
Li-Wei Kuo
MWMichelle M Williams
Michelle M Williams
HLHanne Lind
Hanne Lind
LCLyndsey S. Crump
Lyndsey S. Crump
JRJennifer K. Richer
Jennifer K. Richer
Triple-negative breast cancer (TNBC) often undergoes at least partial epithelial-to-mesenchymal transition (EMT) to facilitate metastasis. Identifying EMT-associated characteristics can reveal novel dependencies that may serve as therapeutic vulnerabilities in this aggressive breast cancer subtype. We found that NPC1, which encodes the lysosomal cholesterol transporter Niemann–Pick type C1 is highly expressed in TNBC as compared to estrogen receptor-positive (ER+) breast cancer, and is significantly elevated in high-grade disease. We demonstrated that NPC1 is directly targeted by microRNA-200c (miR-200c), a potent suppressor of EMT, providing a mechanism for its differential expression in breast cancer subtypes. The silencing of NPC1 in TNBC causes an accumulation of cholesterol-filled lysosomes, and drives decreased growth in soft agar and invasive capacity. Conversely, overexpression of NPC1 in an ER+ cell line increases invasion and growth in soft agar. We further identified TNBC cell lines as cholesterol auxotrophs, however, they do not solely depend on NPC1 for adequate cholesterol supply. The silencing of NPC1 in TNBC cell lines led to altered mitochondrial function and morphology, suppression of mTOR signaling, and accumulation of autophagosomes. A small molecule inhibitor of NPC1, U18666A, decreased TNBC proliferation and synergized with the chemotherapeutic drug, paclitaxel. This work suggests that NPC1 promotes aggressive characteristics in TNBC, and identifies NPC1 as a potential therapeutic target.

2 November 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MWMichelle M Williams
Michelle M Williams
SHSabrina A. Hafeez
Sabrina A. Hafeez
Jessica L. ChristensonJessica L. Christenson
Jessica L. Christenson
KOKathleen O'Neill
Kathleen O'Neill
NHNia G. Hammond
Nia G. Hammond
JRJennifer K. Richer
Jennifer K. Richer
Approval of checkpoint inhibitors for treatment of metastatic triple negative breast cancer (mTNBC) has opened the door for the use of immunotherapies against this disease. However, not all patients with mTNBC respond to current immunotherapy approaches such as checkpoint inhibitors. Recent evidence demonstrates that TNBC metastases are more immune suppressed than primary tumors, suggesting that combination or additional immunotherapy strategies may be required to activate an anti-tumor immune attack at metastatic sites. To identify other immune suppressive mechanisms utilized by mTNBC, our group and others manipulated oncogenic epithelial-to-mesenchymal transition (EMT) programs in TNBC models to reveal differences between this breast cancer subtype and its more epithelial counterpart. This review will discuss how EMT modulation revealed several mechanisms, including tumor cell metabolism, cytokine milieu and secretion of additional immune modulators, by which mTNBC cells may suppress both the innate and adaptive anti-tumor immune responses. Many of these pathways/proteins are under preclinical or clinical investigation as therapeutic targets in mTNBC and other advanced cancers to enhance their response to chemotherapy and/or checkpoint inhibitors.

1 October 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
LKLi-Wei Kuo
Li-Wei Kuo
LCLyndsey S. Crump
Lyndsey S. Crump
KOKathleen O'Neill
Kathleen O'Neill
MWMichelle M Williams
Michelle M Williams
Jessica L. ChristensonJessica L. Christenson
Jessica L. Christenson
JRJennifer K. Richer
Jennifer K. Richer
Anchorage-independent triple-negative breast cancer (TNBC) cells exhibit elevated levels of the tryptophan (TRP)-catabolizing enzyme tryptophan 2,3-dioxygenase 2 (TDO2) compared with the same cells grown under two-dimensional culture conditions. Tracing of 13C11-TRP demonstrated that anchorage-independent culture and/or inflammatory cytokines that activate NF-κB increase TRP catabolism and production of downstream catabolites such as kynurenine, which activate the aryl hydrocarbon receptor (AhR). TDO2 expression is heterogeneous within TNBC cell lines. To determine the function of TDO2, both pharmacologic inhibition and genetic manipulation were conducted. TDO2 knockdown revealed a compensatory increase in indoleamine 2,3-dioxygenase 1 (IDO1), a nonhomologous TRP-catabolizing enzyme, indicating that dual inhibition of these two enzymes is necessary to reliably block TRP catabolism. Thus, we tested a newly developed TDO2/IDO1 dual inhibitor, AT-0174, and found that it effectively inhibits TNBC TRP catabolism. Furthermore, AT-0174 treatment or AhR inhibitor significantly decreased TNBC anchorage-independent survival, invasive capacity, and expression of mesenchymal genes and proteins, whereas exogenous kynurenine increased invasion through AhR-mediated zinc finger E-box–binding homeobox 1 (ZEB1) expression. Thus, dual inhibition of TDO2/IDO1 may prove efficacious against TNBC progression. Significance: TDO2 is more highly expressed than the nonhomologous TRP-catabolizing enzyme IDO1 in TNBC. We find that TDO2 knockdown can lead to a compensatory increase in IDO1. Therefore, we tested a newly developed TDO2/IDO1 dual inhibitor and found that it decreases TRP catabolism, anchorage-independent survival, and invasive capacity.

1 April 2026 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
Jessica L. ChristensonJessica L. Christenson
Jessica L. Christenson
NSNicole S. Spoelstra
Nicole S. Spoelstra
MWMichelle M Williams
Michelle M Williams
LLLinda L. Logan
Linda L. Logan
KOKathleen O'Neill
Kathleen O'Neill
JRJennifer K. Richer
Jennifer K. Richer
When tumor cells colonize distant organs during metastasis, they interact extensively with surrounding cells. These interactions often change the behavior of surrounding cell populations which collectively induce a protumor microenvironment that permits tumor cell outgrowth into overt, clinically detectable metastatic disease. The lung is one of the most common sites of breast cancer metastasis. A chronic wound repair–related phenotype developed within the lung microenvironment during metastatic outgrowth in immunocompetent preclinical mouse models of breast cancer. This phenotype was characterized by an increased number and activation of lung type II alveolar epithelial (AT2) cells surrounding growing metastases. Metastatic outgrowth significantly changed AT2 gene expression, resulting in a modified secretome. AT2-derived secreted factors also promoted triple-negative breast cancer growth. AT2-secreted factors are regulated by the cyclic adenosine monophosphate response element-binding protein (CREB). Targeting CREB signaling with the phosphodiesterase 4 (PDE4) inhibitor roflumilast reduced AT2 breast cancer reciprocal interactions in vitro and metastatic outgrowth in vivo. Finally, AT2 cells adjacent to metastases in lungs from patients with metastatic breast cancer expressed higher PDE4B compared with AT2 cells in normal lungs. Significance: Alveolar epithelial cells are the most common cell type in the lung. Our studies demonstrate the potential for targeting metastasis-associated wound repair and lung epithelial cell activation during metastatic outgrowth with FDA-approved PDE4 inhibitors. This strategy may be an effective way to treat and manage progression of established metastatic breast cancer within the lung.

17 June 2026
Verified
Other
Open access
Jessica L. ChristensonJessica L. Christenson
Jessica L. Christenson
NSNicole S. Spoelstra
Nicole S. Spoelstra
MWMichelle M Williams
Michelle M Williams
LLLinda L. Logan
Linda L. Logan
KOKathleen O'Neill
Kathleen O'Neill
JRJennifer K. Richer
Jennifer K. Richer
Lung scRNAseq Bulk comparison: Low vs High - Pathways.